Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fragile X Syndrome | 30 | 2023 | 188 | 7.930 |
Why?
|
Tremor | 26 | 2022 | 104 | 7.330 |
Why?
|
Fragile X Mental Retardation Protein | 32 | 2023 | 115 | 7.000 |
Why?
|
Parkinson Disease | 33 | 2025 | 670 | 6.710 |
Why?
|
Ataxia | 25 | 2022 | 76 | 6.270 |
Why?
|
Parkinsonian Disorders | 11 | 2022 | 225 | 2.820 |
Why?
|
Heterozygote | 11 | 2022 | 100 | 2.670 |
Why?
|
Trinucleotide Repeat Expansion | 15 | 2023 | 45 | 2.470 |
Why?
|
Tinnitus | 5 | 2020 | 12 | 2.030 |
Why?
|
Neurology | 3 | 2022 | 37 | 1.930 |
Why?
|
Humans | 110 | 2025 | 27072 | 1.880 |
Why?
|
Cognition Disorders | 7 | 2021 | 985 | 1.630 |
Why?
|
Female | 63 | 2025 | 15212 | 1.390 |
Why?
|
Research Design | 6 | 2022 | 185 | 1.320 |
Why?
|
Male | 57 | 2025 | 14772 | 1.300 |
Why?
|
Middle Aged | 51 | 2025 | 8923 | 1.260 |
Why?
|
Aged | 47 | 2025 | 8997 | 1.210 |
Why?
|
Supranuclear Palsy, Progressive | 8 | 2020 | 21 | 1.180 |
Why?
|
Gait Disorders, Neurologic | 3 | 2020 | 133 | 1.150 |
Why?
|
Postural Balance | 5 | 2020 | 117 | 1.130 |
Why?
|
Executive Function | 3 | 2018 | 111 | 1.040 |
Why?
|
Gastrointestinal Microbiome | 3 | 2023 | 158 | 1.040 |
Why?
|
Phenotype | 10 | 2025 | 312 | 1.030 |
Why?
|
Cerebellar Ataxia | 2 | 2021 | 4 | 0.990 |
Why?
|
Trinucleotide Repeats | 2 | 2018 | 11 | 0.960 |
Why?
|
Movement Disorders | 4 | 2016 | 66 | 0.950 |
Why?
|
Health Status Disparities | 1 | 2025 | 75 | 0.900 |
Why?
|
Cognition | 6 | 2022 | 1339 | 0.890 |
Why?
|
Healthcare Disparities | 1 | 2025 | 88 | 0.890 |
Why?
|
Accidental Falls | 4 | 2020 | 110 | 0.860 |
Why?
|
Biomedical Research | 2 | 2018 | 56 | 0.830 |
Why?
|
Exercise Therapy | 3 | 2018 | 88 | 0.810 |
Why?
|
Attention | 2 | 2020 | 124 | 0.770 |
Why?
|
Advance Care Planning | 1 | 2022 | 11 | 0.760 |
Why?
|
Huntington Disease | 1 | 2022 | 48 | 0.740 |
Why?
|
Mutation | 8 | 2023 | 348 | 0.730 |
Why?
|
Spinocerebellar Degenerations | 1 | 2021 | 4 | 0.730 |
Why?
|
Psychomotor Performance | 2 | 2020 | 205 | 0.710 |
Why?
|
Patient Selection | 2 | 2018 | 194 | 0.690 |
Why?
|
Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.670 |
Why?
|
Nootropic Agents | 1 | 2020 | 14 | 0.670 |
Why?
|
Delphi Technique | 3 | 2022 | 25 | 0.660 |
Why?
|
Auditory Perception | 2 | 2017 | 34 | 0.650 |
Why?
|
Walking | 4 | 2020 | 253 | 0.650 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 216 | 0.610 |
Why?
|
Hearing | 2 | 2021 | 20 | 0.610 |
Why?
|
Quality of Life | 7 | 2025 | 629 | 0.600 |
Why?
|
Case-Control Studies | 10 | 2021 | 587 | 0.570 |
Why?
|
Dyskinesia, Drug-Induced | 3 | 2023 | 9 | 0.570 |
Why?
|
Genetic Predisposition to Disease | 5 | 2023 | 381 | 0.570 |
Why?
|
Acoustics | 1 | 2017 | 19 | 0.570 |
Why?
|
Psychotherapy | 1 | 2017 | 39 | 0.550 |
Why?
|
Deafness | 3 | 2022 | 13 | 0.550 |
Why?
|
Polymerase Chain Reaction | 2 | 2016 | 120 | 0.550 |
Why?
|
Adult | 23 | 2022 | 7831 | 0.540 |
Why?
|
United States | 6 | 2025 | 2035 | 0.540 |
Why?
|
Memory Disorders | 2 | 2016 | 159 | 0.540 |
Why?
|
Severity of Illness Index | 11 | 2020 | 879 | 0.530 |
Why?
|
Genetic Testing | 6 | 2021 | 57 | 0.520 |
Why?
|
Cerebral Hemorrhage | 4 | 2021 | 96 | 0.520 |
Why?
|
Antipsychotic Agents | 2 | 2023 | 55 | 0.500 |
Why?
|
Aged, 80 and over | 17 | 2021 | 4777 | 0.500 |
Why?
|
DNA Methylation | 1 | 2016 | 161 | 0.480 |
Why?
|
Treatment Outcome | 11 | 2022 | 3485 | 0.470 |
Why?
|
Neuropsychological Tests | 8 | 2022 | 1196 | 0.440 |
Why?
|
Surveys and Questionnaires | 7 | 2022 | 1144 | 0.430 |
Why?
|
Acoustic Stimulation | 1 | 2013 | 50 | 0.420 |
Why?
|
Risk Factors | 9 | 2021 | 2302 | 0.390 |
Why?
|
Speech Disorders | 2 | 2020 | 10 | 0.390 |
Why?
|
Deep Brain Stimulation | 2 | 2022 | 36 | 0.380 |
Why?
|
Alleles | 3 | 2020 | 216 | 0.380 |
Why?
|
Retrospective Studies | 10 | 2022 | 3538 | 0.370 |
Why?
|
Brain Ischemia | 2 | 2021 | 63 | 0.370 |
Why?
|
Communication Disorders | 1 | 2011 | 4 | 0.360 |
Why?
|
Chromosomes, Human, X | 2 | 2009 | 9 | 0.350 |
Why?
|
Consensus | 3 | 2022 | 87 | 0.350 |
Why?
|
Cochlear Implantation | 2 | 2021 | 22 | 0.340 |
Why?
|
Gait | 4 | 2020 | 412 | 0.340 |
Why?
|
Activities of Daily Living | 4 | 2017 | 595 | 0.340 |
Why?
|
Dopamine | 1 | 2010 | 82 | 0.340 |
Why?
|
Walking Speed | 2 | 2022 | 41 | 0.330 |
Why?
|
Shoulder Pain | 1 | 2010 | 57 | 0.330 |
Why?
|
Sex Chromosome Aberrations | 1 | 2009 | 1 | 0.330 |
Why?
|
Chromosomes, Human, Y | 1 | 2009 | 1 | 0.330 |
Why?
|
Speech Perception | 2 | 2021 | 49 | 0.330 |
Why?
|
Levodopa | 3 | 2023 | 34 | 0.330 |
Why?
|
Cognitive Dysfunction | 2 | 2020 | 1061 | 0.320 |
Why?
|
DNA Repeat Expansion | 2 | 2006 | 6 | 0.310 |
Why?
|
Prospective Studies | 7 | 2025 | 1778 | 0.310 |
Why?
|
Quinolones | 1 | 2009 | 11 | 0.310 |
Why?
|
Pilot Projects | 3 | 2020 | 420 | 0.310 |
Why?
|
Motor Activity | 3 | 2021 | 323 | 0.310 |
Why?
|
Cross-Sectional Studies | 6 | 2020 | 891 | 0.300 |
Why?
|
Sex Factors | 4 | 2022 | 464 | 0.290 |
Why?
|
Piperazines | 1 | 2009 | 85 | 0.290 |
Why?
|
Observational Studies as Topic | 2 | 2025 | 22 | 0.280 |
Why?
|
Students, Health Occupations | 1 | 2007 | 4 | 0.280 |
Why?
|
Science | 1 | 2007 | 4 | 0.280 |
Why?
|
Celiac Disease | 1 | 2007 | 7 | 0.280 |
Why?
|
Dystonia | 1 | 2007 | 12 | 0.280 |
Why?
|
Clinical Laboratory Techniques | 1 | 2007 | 29 | 0.270 |
Why?
|
Teaching | 1 | 2007 | 51 | 0.270 |
Why?
|
RNA, Messenger | 4 | 2023 | 310 | 0.270 |
Why?
|
Fetal Distress | 1 | 2006 | 1 | 0.270 |
Why?
|
Pregnancy in Diabetics | 1 | 2006 | 4 | 0.270 |
Why?
|
Central Nervous System Agents | 1 | 2006 | 7 | 0.270 |
Why?
|
Age of Onset | 4 | 2016 | 94 | 0.270 |
Why?
|
Infant, Newborn, Diseases | 1 | 2006 | 15 | 0.260 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2006 | 17 | 0.260 |
Why?
|
Seizures | 1 | 2006 | 67 | 0.250 |
Why?
|
Feces | 2 | 2023 | 103 | 0.250 |
Why?
|
Gait Ataxia | 1 | 2005 | 5 | 0.250 |
Why?
|
Disability Evaluation | 5 | 2016 | 264 | 0.250 |
Why?
|
Cohort Studies | 5 | 2023 | 1890 | 0.240 |
Why?
|
Glucosylceramidase | 2 | 2022 | 15 | 0.240 |
Why?
|
Prion Diseases | 1 | 2005 | 2 | 0.240 |
Why?
|
Diagnostic Errors | 1 | 2005 | 28 | 0.240 |
Why?
|
Prions | 1 | 2005 | 7 | 0.240 |
Why?
|
Brain | 5 | 2022 | 1649 | 0.230 |
Why?
|
Exercise | 3 | 2017 | 450 | 0.230 |
Why?
|
Time Factors | 5 | 2020 | 1433 | 0.230 |
Why?
|
Intellectual Disability | 1 | 2005 | 43 | 0.230 |
Why?
|
Hyperglycinemia, Nonketotic | 1 | 2004 | 1 | 0.230 |
Why?
|
Neurotoxicity Syndromes | 1 | 2004 | 3 | 0.230 |
Why?
|
Chorea | 1 | 2004 | 5 | 0.230 |
Why?
|
Eye Movements | 2 | 2021 | 11 | 0.230 |
Why?
|
Child | 5 | 2022 | 1295 | 0.210 |
Why?
|
Antiparkinson Agents | 1 | 2023 | 42 | 0.210 |
Why?
|
Corpus Callosum | 1 | 2003 | 12 | 0.210 |
Why?
|
Basal Ganglia Diseases | 1 | 2023 | 5 | 0.210 |
Why?
|
Diffusion Magnetic Resonance Imaging | 2 | 2021 | 89 | 0.210 |
Why?
|
Mental Disorders | 1 | 2005 | 141 | 0.210 |
Why?
|
Incidence | 4 | 2020 | 759 | 0.210 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 18 | 0.210 |
Why?
|
Caregivers | 2 | 2022 | 197 | 0.210 |
Why?
|
Fatty Acids, Volatile | 1 | 2023 | 31 | 0.210 |
Why?
|
Prebiotics | 1 | 2023 | 22 | 0.200 |
Why?
|
Career Mobility | 1 | 2022 | 13 | 0.200 |
Why?
|
ran GTP-Binding Protein | 1 | 2022 | 3 | 0.200 |
Why?
|
Health Facilities | 1 | 2022 | 23 | 0.200 |
Why?
|
Homebound Persons | 1 | 2022 | 6 | 0.200 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 1 | 2022 | 17 | 0.200 |
Why?
|
Neurosecretory Systems | 1 | 2022 | 5 | 0.200 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2022 | 9 | 0.200 |
Why?
|
Longitudinal Studies | 3 | 2021 | 1368 | 0.200 |
Why?
|
Mentoring | 1 | 2022 | 27 | 0.200 |
Why?
|
Weather | 2 | 2019 | 11 | 0.190 |
Why?
|
Advance Directives | 1 | 2022 | 3 | 0.190 |
Why?
|
Biomechanical Phenomena | 4 | 2020 | 644 | 0.190 |
Why?
|
Alzheimer Disease | 1 | 2014 | 2109 | 0.190 |
Why?
|
Cerebral Infarction | 1 | 2003 | 147 | 0.190 |
Why?
|
Documentation | 1 | 2022 | 24 | 0.190 |
Why?
|
Subthalamic Nucleus | 1 | 2022 | 19 | 0.190 |
Why?
|
Dopamine Agents | 1 | 2021 | 11 | 0.190 |
Why?
|
Multiple System Atrophy | 1 | 2022 | 32 | 0.190 |
Why?
|
Food | 1 | 2021 | 34 | 0.190 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2021 | 8 | 0.180 |
Why?
|
Comprehension | 2 | 2016 | 31 | 0.180 |
Why?
|
Ovary | 1 | 2021 | 23 | 0.180 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2021 | 14 | 0.180 |
Why?
|
Cerebral Amyloid Angiopathy | 2 | 2019 | 111 | 0.180 |
Why?
|
Hypertension | 2 | 2019 | 192 | 0.180 |
Why?
|
Societies, Medical | 2 | 2019 | 121 | 0.180 |
Why?
|
Chicago | 2 | 2021 | 949 | 0.180 |
Why?
|
Martial Arts | 1 | 2020 | 4 | 0.180 |
Why?
|
Hyperglycemia | 1 | 2020 | 29 | 0.180 |
Why?
|
Telemedicine | 1 | 2022 | 97 | 0.170 |
Why?
|
Neurodegenerative Diseases | 1 | 2022 | 125 | 0.170 |
Why?
|
Prevalence | 2 | 2020 | 443 | 0.170 |
Why?
|
Vision Disorders | 1 | 2020 | 20 | 0.170 |
Why?
|
Menopause | 1 | 2021 | 101 | 0.170 |
Why?
|
Hearing Loss, Unilateral | 1 | 2020 | 1 | 0.170 |
Why?
|
Animals | 5 | 2022 | 3642 | 0.170 |
Why?
|
Hearing Aids | 1 | 2020 | 3 | 0.170 |
Why?
|
Blood Glucose | 1 | 2020 | 104 | 0.170 |
Why?
|
Time and Motion Studies | 1 | 2020 | 19 | 0.170 |
Why?
|
Chemokine CCL5 | 1 | 2019 | 14 | 0.160 |
Why?
|
Dementia | 1 | 2005 | 560 | 0.160 |
Why?
|
Th17 Cells | 1 | 2019 | 30 | 0.160 |
Why?
|
Predictive Value of Tests | 4 | 2020 | 474 | 0.160 |
Why?
|
Electroencephalography | 2 | 2013 | 77 | 0.160 |
Why?
|
Research Subjects | 1 | 2018 | 10 | 0.160 |
Why?
|
Academies and Institutes | 1 | 2018 | 11 | 0.160 |
Why?
|
Sample Size | 1 | 2018 | 18 | 0.150 |
Why?
|
Health Services Accessibility | 1 | 2020 | 112 | 0.150 |
Why?
|
Adolescent | 4 | 2013 | 2172 | 0.150 |
Why?
|
Genotype | 3 | 2016 | 346 | 0.150 |
Why?
|
Dopaminergic Neurons | 1 | 2019 | 49 | 0.150 |
Why?
|
Substantia Nigra | 1 | 2019 | 120 | 0.150 |
Why?
|
Pedigree | 3 | 2008 | 65 | 0.150 |
Why?
|
Independent Living | 1 | 2021 | 322 | 0.150 |
Why?
|
High-Intensity Interval Training | 1 | 2018 | 1 | 0.150 |
Why?
|
Gene-Environment Interaction | 1 | 2018 | 18 | 0.150 |
Why?
|
Estrogens | 1 | 2018 | 25 | 0.150 |
Why?
|
Ibuprofen | 1 | 2017 | 11 | 0.140 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 77 | 0.140 |
Why?
|
Stakeholder Participation | 1 | 2017 | 10 | 0.140 |
Why?
|
Endpoint Determination | 1 | 2017 | 22 | 0.140 |
Why?
|
Fatigue Syndrome, Chronic | 1 | 2017 | 3 | 0.140 |
Why?
|
Colorado | 2 | 2007 | 4 | 0.140 |
Why?
|
Memory, Short-Term | 2 | 2015 | 97 | 0.140 |
Why?
|
Exercise Test | 1 | 2018 | 118 | 0.140 |
Why?
|
Mosaicism | 1 | 2016 | 9 | 0.140 |
Why?
|
Siblings | 1 | 2016 | 15 | 0.140 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 164 | 0.140 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 110 | 0.130 |
Why?
|
Congresses as Topic | 1 | 2016 | 32 | 0.130 |
Why?
|
Water Wells | 1 | 2016 | 1 | 0.130 |
Why?
|
Uric Acid | 1 | 2016 | 7 | 0.130 |
Why?
|
Follow-Up Studies | 4 | 2010 | 1792 | 0.130 |
Why?
|
Epigenesis, Genetic | 1 | 2016 | 83 | 0.130 |
Why?
|
Environmental Exposure | 1 | 2016 | 17 | 0.130 |
Why?
|
Age Factors | 4 | 2021 | 766 | 0.130 |
Why?
|
Occupational Diseases | 1 | 2016 | 22 | 0.130 |
Why?
|
Computers | 1 | 2015 | 17 | 0.130 |
Why?
|
Hip Prosthesis | 1 | 2021 | 539 | 0.120 |
Why?
|
Early Diagnosis | 1 | 2015 | 57 | 0.120 |
Why?
|
Chronic Disease | 1 | 2017 | 415 | 0.120 |
Why?
|
Reaction Time | 1 | 2015 | 102 | 0.120 |
Why?
|
DNA Mutational Analysis | 2 | 2005 | 56 | 0.120 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 68 | 0.120 |
Why?
|
Young Adult | 3 | 2013 | 1994 | 0.120 |
Why?
|
Regression Analysis | 1 | 2015 | 260 | 0.120 |
Why?
|
Range of Motion, Articular | 1 | 2018 | 708 | 0.120 |
Why?
|
Endometrium | 2 | 2002 | 8 | 0.120 |
Why?
|
Dopamine Agonists | 2 | 2021 | 15 | 0.110 |
Why?
|
Breast Neoplasms | 4 | 1997 | 409 | 0.110 |
Why?
|
Hyperkinesis | 1 | 2013 | 8 | 0.110 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2013 | 18 | 0.110 |
Why?
|
Auditory Pathways | 1 | 2013 | 1 | 0.110 |
Why?
|
Audiometry, Pure-Tone | 1 | 2013 | 12 | 0.110 |
Why?
|
England | 1 | 2013 | 14 | 0.110 |
Why?
|
Psychoacoustics | 1 | 2013 | 7 | 0.110 |
Why?
|
Diagnosis, Differential | 2 | 2005 | 348 | 0.110 |
Why?
|
Disease Progression | 4 | 2016 | 673 | 0.110 |
Why?
|
Cerebellar Diseases | 1 | 2013 | 8 | 0.110 |
Why?
|
Registries | 2 | 2022 | 189 | 0.110 |
Why?
|
Clinical Protocols | 1 | 2013 | 57 | 0.100 |
Why?
|
Neuronal Plasticity | 1 | 2013 | 47 | 0.100 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2021 | 810 | 0.100 |
Why?
|
Equipment Design | 1 | 2013 | 138 | 0.100 |
Why?
|
Tamoxifen | 1 | 1993 | 30 | 0.100 |
Why?
|
Breast | 3 | 1998 | 28 | 0.100 |
Why?
|
Magnetic Resonance Imaging | 3 | 2016 | 1112 | 0.100 |
Why?
|
Biopsy | 2 | 2007 | 201 | 0.100 |
Why?
|
House Calls | 2 | 2022 | 15 | 0.100 |
Why?
|
Double-Blind Method | 1 | 2013 | 406 | 0.100 |
Why?
|
Neurologic Examination | 3 | 2008 | 100 | 0.100 |
Why?
|
Infant, Newborn | 2 | 2021 | 642 | 0.090 |
Why?
|
Genome-Wide Association Study | 2 | 2023 | 280 | 0.090 |
Why?
|
Social Behavior Disorders | 1 | 2011 | 5 | 0.090 |
Why?
|
Language Disorders | 1 | 2011 | 7 | 0.090 |
Why?
|
Memantine | 1 | 2010 | 9 | 0.090 |
Why?
|
Cyclohexanols | 1 | 2010 | 18 | 0.090 |
Why?
|
Mammography | 4 | 1998 | 47 | 0.090 |
Why?
|
Cocaine | 1 | 2010 | 31 | 0.090 |
Why?
|
Point Mutation | 2 | 2008 | 25 | 0.090 |
Why?
|
Odds Ratio | 1 | 2011 | 270 | 0.090 |
Why?
|
Corpus Striatum | 1 | 2010 | 65 | 0.080 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 79 | 0.080 |
Why?
|
Family Health | 2 | 2007 | 34 | 0.080 |
Why?
|
Herpes Zoster | 1 | 2009 | 4 | 0.080 |
Why?
|
Atmospheric Pressure | 2 | 2019 | 6 | 0.080 |
Why?
|
Brown-Sequard Syndrome | 1 | 2009 | 4 | 0.080 |
Why?
|
Aripiprazole | 1 | 2009 | 7 | 0.080 |
Why?
|
Atrophy | 2 | 2008 | 91 | 0.080 |
Why?
|
Biomarkers | 2 | 2022 | 562 | 0.080 |
Why?
|
Palate, Soft | 1 | 2008 | 1 | 0.070 |
Why?
|
Alexander Disease | 1 | 2008 | 1 | 0.070 |
Why?
|
Heredodegenerative Disorders, Nervous System | 1 | 2008 | 2 | 0.070 |
Why?
|
Genetic Carrier Screening | 1 | 2007 | 10 | 0.070 |
Why?
|
Child, Preschool | 1 | 2009 | 641 | 0.070 |
Why?
|
Exercise Tolerance | 1 | 2007 | 31 | 0.070 |
Why?
|
Guidelines as Topic | 1 | 2007 | 57 | 0.070 |
Why?
|
Glutens | 1 | 2007 | 1 | 0.070 |
Why?
|
Jejunum | 1 | 2007 | 10 | 0.070 |
Why?
|
Chromosome Mapping | 1 | 2007 | 42 | 0.070 |
Why?
|
Research Support as Topic | 1 | 2007 | 14 | 0.070 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2007 | 25 | 0.070 |
Why?
|
Education | 1 | 2007 | 40 | 0.070 |
Why?
|
North America | 2 | 2018 | 41 | 0.070 |
Why?
|
Universities | 1 | 2007 | 39 | 0.070 |
Why?
|
Carbidopa | 1 | 2006 | 4 | 0.070 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2007 | 28 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 2 | 2004 | 683 | 0.070 |
Why?
|
Cholinesterase Inhibitors | 1 | 2006 | 14 | 0.070 |
Why?
|
Benzodiazepines | 1 | 2006 | 46 | 0.070 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2006 | 26 | 0.070 |
Why?
|
Internet | 1 | 2007 | 91 | 0.060 |
Why?
|
Intestinal Mucosa | 1 | 2007 | 156 | 0.060 |
Why?
|
Population Surveillance | 1 | 2006 | 115 | 0.060 |
Why?
|
Syndrome | 1 | 2005 | 76 | 0.060 |
Why?
|
Pregnancy | 1 | 2006 | 336 | 0.060 |
Why?
|
Cerebellum | 1 | 2005 | 43 | 0.060 |
Why?
|
Anxiety Disorders | 1 | 2006 | 171 | 0.060 |
Why?
|
Health Surveys | 1 | 2005 | 86 | 0.060 |
Why?
|
RNA-Binding Proteins | 1 | 2004 | 24 | 0.060 |
Why?
|
Disease Models, Animal | 2 | 2019 | 599 | 0.050 |
Why?
|
Linkage Disequilibrium | 1 | 2023 | 43 | 0.050 |
Why?
|
Agraphia | 1 | 2003 | 1 | 0.050 |
Why?
|
Dyslexia, Acquired | 1 | 2003 | 1 | 0.050 |
Why?
|
Auditory Perceptual Disorders | 1 | 2003 | 2 | 0.050 |
Why?
|
Genetic Loci | 1 | 2023 | 51 | 0.050 |
Why?
|
Metagenome | 1 | 2023 | 17 | 0.050 |
Why?
|
Nerve Tissue Proteins | 1 | 2004 | 154 | 0.050 |
Why?
|
Uterine Diseases | 1 | 2002 | 2 | 0.050 |
Why?
|
Mentors | 1 | 2022 | 36 | 0.050 |
Why?
|
Guanine | 1 | 2022 | 5 | 0.050 |
Why?
|
Endometriosis | 1 | 2002 | 16 | 0.050 |
Why?
|
Task Performance and Analysis | 2 | 2013 | 47 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2023 | 278 | 0.050 |
Why?
|
Butyrates | 1 | 2022 | 17 | 0.050 |
Why?
|
Neurons | 1 | 2005 | 339 | 0.050 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 261 | 0.050 |
Why?
|
Stroke | 1 | 2005 | 261 | 0.050 |
Why?
|
Dysbiosis | 1 | 2022 | 45 | 0.050 |
Why?
|
Bacteria | 1 | 2022 | 70 | 0.050 |
Why?
|
Peptides | 1 | 2022 | 102 | 0.050 |
Why?
|
Genetic Background | 1 | 2021 | 2 | 0.050 |
Why?
|
Physical Therapy Modalities | 2 | 2012 | 74 | 0.050 |
Why?
|
Drosophila melanogaster | 1 | 2021 | 15 | 0.050 |
Why?
|
Animals, Genetically Modified | 1 | 2021 | 19 | 0.050 |
Why?
|
Fertility | 1 | 2021 | 18 | 0.050 |
Why?
|
Cross-Over Studies | 1 | 2021 | 64 | 0.040 |
Why?
|
Proteome | 1 | 2021 | 41 | 0.040 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2021 | 143 | 0.040 |
Why?
|
Surface Properties | 1 | 2021 | 135 | 0.040 |
Why?
|
Life Style | 1 | 2022 | 186 | 0.040 |
Why?
|
Corrosion | 1 | 2021 | 126 | 0.040 |
Why?
|
Materials Testing | 1 | 2021 | 129 | 0.040 |
Why?
|
Inflammation | 1 | 2022 | 272 | 0.040 |
Why?
|
Databases, Factual | 1 | 2022 | 347 | 0.040 |
Why?
|
Noise | 1 | 2020 | 24 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2020 | 220 | 0.040 |
Why?
|
Logistic Models | 2 | 2018 | 395 | 0.040 |
Why?
|
Cochlear Implants | 1 | 2020 | 28 | 0.040 |
Why?
|
Nerve Degeneration | 1 | 2019 | 48 | 0.040 |
Why?
|
Biopsy, Needle | 2 | 1996 | 105 | 0.040 |
Why?
|
Temperature | 1 | 2018 | 63 | 0.040 |
Why?
|
Prosthesis Design | 1 | 2021 | 490 | 0.040 |
Why?
|
Risk Assessment | 1 | 2021 | 624 | 0.040 |
Why?
|
Breast Diseases | 1 | 1998 | 7 | 0.040 |
Why?
|
Hospitalization | 1 | 2020 | 300 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 785 | 0.040 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 420 | 0.040 |
Why?
|
Comorbidity | 1 | 2019 | 481 | 0.040 |
Why?
|
Prosthesis Failure | 1 | 2021 | 523 | 0.030 |
Why?
|
Self Report | 1 | 2018 | 223 | 0.030 |
Why?
|
Accelerometry | 1 | 2017 | 89 | 0.030 |
Why?
|
Posture | 1 | 2016 | 63 | 0.030 |
Why?
|
Protective Factors | 1 | 2016 | 26 | 0.030 |
Why?
|
Occupational Exposure | 1 | 2016 | 17 | 0.030 |
Why?
|
Radiography, Interventional | 1 | 1996 | 17 | 0.030 |
Why?
|
Practice Patterns, Physicians' | 1 | 1997 | 111 | 0.030 |
Why?
|
Neuroimaging | 1 | 2016 | 126 | 0.030 |
Why?
|
Mice | 1 | 2019 | 1395 | 0.030 |
Why?
|
Video Recording | 1 | 2014 | 31 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2013 | 102 | 0.030 |
Why?
|
Movement | 1 | 2013 | 112 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 302 | 0.020 |
Why?
|
Mental Health | 1 | 2013 | 108 | 0.020 |
Why?
|
Health Status | 1 | 2013 | 218 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 125 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 139 | 0.020 |
Why?
|
Mass Screening | 2 | 2007 | 167 | 0.020 |
Why?
|
Venlafaxine Hydrochloride | 1 | 2010 | 17 | 0.020 |
Why?
|
Linear Models | 1 | 2011 | 247 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 161 | 0.020 |
Why?
|
Geniculate Ganglion | 1 | 2009 | 1 | 0.020 |
Why?
|
Superior Cervical Ganglion | 1 | 2009 | 1 | 0.020 |
Why?
|
Pons | 1 | 2008 | 5 | 0.020 |
Why?
|
Intelligence | 1 | 2008 | 18 | 0.020 |
Why?
|
Mental Processes | 1 | 2008 | 17 | 0.020 |
Why?
|
Verbal Learning | 1 | 2008 | 33 | 0.020 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2008 | 43 | 0.020 |
Why?
|
Gene Silencing | 1 | 2007 | 23 | 0.020 |
Why?
|
Patient Compliance | 1 | 2007 | 150 | 0.020 |
Why?
|
California | 1 | 2004 | 34 | 0.010 |
Why?
|
Leiomyoma | 1 | 2002 | 5 | 0.010 |
Why?
|
Uterine Neoplasms | 1 | 2002 | 11 | 0.010 |
Why?
|
Ultrasonography | 1 | 2002 | 227 | 0.010 |
Why?
|
Diagnostic Tests, Routine | 1 | 1998 | 12 | 0.010 |
Why?
|
Age Distribution | 1 | 1996 | 85 | 0.010 |
Why?
|
Palpation | 1 | 1996 | 4 | 0.010 |
Why?
|